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Background: Plasma cell leukemia (PCL) is a rare lymphoproliferative disorder, accounting for 1-2% of all plasma
cell neoplasms, characterized by the presence of >2 × 109/l of plasma cells circulating in the peripheral blood, and
exists in two forms: primary PCL (pPCL, 60% of the cases), and secondary PCL (sPCL), the latter being a leukemic
transformation in patients with a previously diagnosed multiple myeloma. PCL is an aggressive disease with poor
prognosis and a short median survival of 7 months.
Results: Here, we report a pPCL case with hepatosplenomegaly, anemia, thrombocytopenia, fever, fatigue, weight
loss, and plasma cell count up to 60% in peripheral blood and 80% in bone marrow. Immunophenotype was
compatible with PCL. A del(9)(p22.3) was characterized using banding cytogenetics and array-proven multicolor
banding (aMCB), the latter being of enormous significance to characterize breakpoint regions in detail.
Conclusion: To the best of our knowledge, this is the first report of pPCL associated with a partially monosomy
9pter to 9p22.3 as a sole chromosomal abnormality.
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Prognostic factorsBackground
Plasma cell leukemia (PCL) is a rare lymphoproliferative
disorder, accounting for 1-2% of all plasma cell neoplasms
[1]. It is defined by the presence of more than 20% plasma
cells in peripheral blood and an absolute plasma cell count
greater than 2 × 109/L [1]. PCL can be classified into two
types. The primary form (pPCL), it occurs de novo in the
absence of a prior history of multiple myeloma (MM) and
it presents in 60% of PCL cases, and a secondary form
(sPCL) with a history of plasma cell myeloma (PCM)
which have progressed to a leukemic phase [1,2].
Clinically, patients with primary PCL have a higher
incidence of hepatosplenomegaly and lymphadenopathy,
and less lytic bone lesions [3]. Prognostic indexes such
as B2-microglobulin, plasma cells in S-phase, proteinuria,
calcium levels, LDH and renal function usually are found
to be significantly higher in PCL than in MM [2].* Correspondence: ascientific@aec.org.sy
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reproduction in any medium, provided the orPCL is highly aggressive, with unsatisfactory responses
to therapy, a poor prognosis, and a median survival of
7 months [2]. Due to the low frequency of this entity, most
publications on PCL are based on case reports, only a few
series exist with more than 20 patients in the medical lit-
erature, and difficulties remain in defining the biological,
clinical, and prognostic features of the disease [2,3].
Here we reported a new case of pPCL with a del(9)
(p22.3), which was characterized by array-proven multi-
color banding (aMCB); also the case had an immuno-
phenotype result consistent with PCL.
Methods
Case report
A 57-year-old male was diagnosed as suffering from
pPCL. Hepatosplenomegaly, anemia, thrombocytopenia,
fever, fatigue, and weight loss were the indicative symp-
toms. His hematologic parameters were: white blood
cells (WBC) of 2.7 × 109/l with 60% plasma cells, red
blood cell (RBC) count was 3.48 × 106/mm3, hemoglobin
level was 10.6 g/dl and the platelet count was 67 × 109/l.
The serum creatinine was 1.07 mg/100 ml (normal levelLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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level up to 10.2 mg/100 ml); serum lactate dehydrogenase
(LDH) level was 662 U/l (normal level up to 480 U/l);
serum aspartate aminotrasferase (AST) level was 42 U/l
(normal up to 40 U/l); and serum ß2-microglobulin level
was 4.12 mg/l (normal level up to 2.3 mg/l). Total serum
protein was within normal range at 7.3 gm/dl (normal
value 6-8.5 gm/dl) but serum albumin was 3.4 gm/dl
(normal value 3.8-5 gm/dl); serum IgG level was 812 mg/
dl (700-1600 mg/dl); serum IgA level was 140 gm/dl
(70-400 mg/dl); and serum IgD level was 48.9 mg/dl
(40-230 mg/dl). Bone marrow aspiration revealed an 80%
of plasma cells. No treatment had been administered prior
to the test.
All human studies have been approved by the ethics
committee of the Atomic Energy Commission, Damascus,
Syria and have therefore been performed in accordance
with the ethical standards laid down in the 1964 Declar-
ation of Helsinki and its later amendments. The patient
gave his informed consent prior to its inclusion in this
study.
Chromosome analysis
Chromosome analysis using GTG-banding was performed
according to standard procedure prior chemotherapeutic
treatment [4]. A total of 20 metaphase cells derived
from unstimulated bone marrow culture were analyzed.
Karyotypes were described according to the International
System for Human Cytogenetic Nomenclature (ISCN) [5].
Molecular cytogenetics
FISH using a chromosome-9-specific aMCB probe set
based on microdissection derived region-specific libraries
was done as previously reported [4]. Also paints for
whole chromosomes 11 and 14 (wcp-probes) were ap-
plied (MetaSystems, Altlussheim, Germany) accordingFigure 1 Cytogenetics and molecular cytogenetics results. (A). GTG-ba
highlighted by arrow head. (B). The application of aMCB(9) characterized th
der = derivative chromosome.to manufacturer’s instructions. A total of 20 metaphase
spreads were analyzed, each using a fluorescence micro-
scope (AxioImager.Z1 mot, Zeiss) equipped with appro-
priate filter sets to discriminate between a maximum
of five fluorochromes plus the counterstain DAPI
(4',6-diamino-2-phenylindole). Image capturing and
processing were carried out using an ISIS imaging
system (MetaSystems, Altlussheim, Germany).
Flow cytometric immunophenotype
Immunophenotyping was performed according to [6].
Manufacturer’s instructions (BD Biosciences) were also
considered. Flow cytometric analysis was performed
using a general panel of fluorescent antibodies against
the following antigens typical for different cell lineages
and cell types: CD1a, CD2, CD3, CD4, CD5, CD8,
CD10, CD11b, CD11c, CD13, CD14, CD15, CD16,
CD19, CD20, CD22, CD23, CD32, CD33, CD34, CD38,
CD41a, CD45, CD56, CD57, CD64, CD103, CD117,
CD123, CD138, CD209, CD235a and CD243; In addition
to antibodies to Kappa and Lambda light Chains, IgD,
sIgM, and HLADr. All antibodies purchased from BD
Biosciences. Samples analyzed on a BD FACSCalibur™
flow cytometer. Autofluorescence, viability, and isotype
controls were included. Flow cytometric data acquisition
and analysis conducted by BD Cellquest™ Pro software.
Interpretations of flow cytometric results were according
to [7].
Results
Pathology results showed that bone marrow specimen
had very high cellularity. Bone marrow consisted of a
morphologically homogenous abnormal cell population
having plasma cell features.
Prior to chemotherapy treatment banding in cytogen-
etics revealed a karyotype 46,XY[12]/46,XY,del(9)(p?)[8]nding revealed a del(9)(p22.3). The derivative chromosome is
e del(9)(p22.3) comprehensively. Abbreviations: # = chromosome;
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chromosome 9 revealed a deletion a part of short arm of
chromosome 9 was present (Figure 1B). The final karyo-
type was determined as: 46,XY[12]/46,XY,del(9)(p22.3)[8]
as a t(11;14)(q13;q32) could be excluded using wcp probes
(results not shown).
The abnormal cell population showed the following
immunophenotype: CD45+dim(80%), HLADr+(78%), CD10+
(80%), CD38+bright (88%), CD22+(64%), CD117+(73%),
CD19+(80%), CD20+(64%), CD32+ (63%) and expressed
CD13 (16%), CD138 (30%), CD15 (24%), sIgM (52%)
heterogeneously. This population negatively reacted with
antibodies to CD34, CD243, CD16, CD56, CD2 CD3,
CD5, CD23, CD11c and CD103. CD138 expression was
heterogeneous; although abnormal cell population repre-
sented 80% of all cells in lymphocytes gate, only 30% of
those were CD138 positive. Expression of surface IgM was
dim and heterogeneous; only 52% of abnormal cells in the
lymphocytes gate reacted positively with mouse anti-
human IgM (isotype IgG1-Kappa, clone G20-127). Over-
all, this immunophenotype was mostly consistent with
PCL [7].
Discussion
PCL is a rare entity; we described a case of pPCL with a
de novo del(9)(p22.3). To the best of our knowledge, the
present case is the only one ever seen with this kind of
aberration [8].
According to the literature, the plasma cells have a
characteristic phenotype: Strong expression of CD38 and
CD19 and weak expression of CD56. In contrast to
normal plasma cells, myeloma cells are often immature
and may have the plasmablastic appearance [9]. While the
expression of CD19 is usually negative, myeloma cells
express CD56 antigen strongly along with CD38 [10].
Plasma cells in PCL display a more immature pheno-
type than in MM, as to be assessed by expression of
CD20 antigen, the latter being usually absent in MM
[11]. In addition plasma cells in PCL frequently lack
CD56 antigen, which has been considered important in
anchoring plasma cells to bone marrow stroma [12].
Immunophenotypic expression is similar in PCL and
MM for CD38, CD138, CD2, CD3, CD6, CD10, CD13
and CD15 [3]. The phenotypic differences do not allow a
complete discrimination between PCL and MM, but
help to explain the differences in survival, since CD56
expression has been associated with good prognosis
while CD20 expression has been associated with a
shorter survival [13].
Recent attempts at genetic and molecular profiling of
PCL have provided important clues to its biology. Using
karyotyping, cytogenetic abnormalities have been identi-
fied in over 70% of PCL patients. Hypodiploidy and com-
plex karyotypes with multiple numerical and structuralabnormalities involving chromosome 1, 13, and 14 have
been identified in a significant number of PCL cases [14].
Molecular genetic abnormalities including del(13q), del
(17p), t(11;14), t(4;14), t(4;16) del(1)(p21), and 1q21-
amplifications have been reported [1,14].
Primary PCL has a more aggressive course high
frequency of extramedullary involvement (liver, spleen,
lymph nodes, extra osseous plasmacytomas etc.), throm-
bocytopenia, anemia, hypercalcemia and impaired renal
function [3]. PCL displays multiple adverse prognostic
indicators at presentation such as elevated LDH, ele-
vated ß2-microglobulin, hypercalcemia, high percentage
of Bence-Jones proteinemia, and extramedullary in-
volvement [13].
The prognosis for pPCL is unfavorable, with a median
overall survival of 7 months [2]. In preceding reports,
the unfavorable prognostic risk factors were a lack of
response to treatment, the increased levels of LDH, and
the peripheral plasma cell count [15]. Deletions in 9p
are found in about 9% of cases of adult acute lympho-
blastic leukemia. The prognostic impact of deletions in
9p has been discussed controversial [16].
In conclusion, we reported a de novo case of pPCL
with a new cytogenetic abnormality, a partial monosomy
9pter to 9p22.3. Overall this finding may be regarded as
unfavorable prognostic parameter in PCL, however, it
could not be confirmed in the present case, as the
patient was lost during follow-up.
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